Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Immunome Inc. (IMNM)
A forensic read on Immunome Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
12.8
Altman Z-score
Clean
Earnings quality
3
Forensic signals
-51.1%
ROE
$2.3B
Market cap
Immunome Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 12.8, placing it in the Safe zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-567%Return on invested capital.Return on invested capital is -567% and rising from -959% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+206.8%/yrShare-count dilution.Diluted share count changed +620% over the last 3 years to FY2025 (+206.8%/yr). The count is GROWING — existing holders are being diluted. That's ~206.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~620%.
370% of revStock-based comp load.Stock-based compensation ran 370% of revenue in FY2025 — about $0.29 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-3060.0%
Debt / Equity0.00x
Free Cash Flow$-200.6M
Latest Revenue$6.9M
Return on Equity-33.5%
Revenue Growth YoY-23.2%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Immunome Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about IMNM's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown